Smoking Cessation: What do Pharmacists Need to Know?

As per Health Canada, - 17% of Canadians (i.e. 4.9 million) are active smokers of 15 years and older. According to the Canadian Cancer Society (Smokers Help Line) , 47,000 Canadians die from smoking each year, and lung cancer (although preventable) is the leading cause of cancer death for both men and women in Canada.

Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: A Meta- Analysis

Hypertension is a major risk factor to coronary artery disease and stroke being its control a cornerstone on primary and secondary prevention. Catheter ablation of the renal sympathetic innervations is a new and promising therapy but data is still limited. We aimed to evaluate its effectiveness in a meta-analysis of the available clinical trials.

Pectoralis Major Muscle Flap in the Treatment of Post CABG Sternal Defects

The incidence of infected sternotomy wounds after median sternotomy for cardiovascular surgery is about (0.5% to 5%) and it is associated with significant morbidity and a long period of treatment. Today, muscle flaps, such as the Pectoralis major, are widely accepted as a mainstay of reconstructive options. A wide variety of modifications of the Pectoralis muscle flap for coverage of sternal defects are available depending upon the location of defect use of internal mammary artery. We would like to share our experience with Pectoralis major muscle flaps to cover the sternal defects.

Association of Carotid Intima Media Thickness and Periscope Markers with Coronary Artery Disease, Risk factors and Biomarkers in Asian Indians

Surrogate sub clinical markers provide an important dimension to cardiovascular risk stratification. We studied the association of carotid intima media thickness (CIMT) and Periscope markers with CAD, classical risk factors and cardiac biomarkers in a cohort of 125 CAD patients with strong family history of cardiovascular disease and 585 unaffected family members selected from the Indian Atherosclerosis Research Study.

B2 Adrenergic Receptor Polymorphisms and Treatment- Outcomes in Cardiovascular Diseases

Cardiovascular diseases (CVD) represent the major health problem in the western world and heavy social and economic burden. Under this name an eterogenous group of multifactorial conditions is included. There is appreciable inter-individual variability in the susceptibility to cardiovascular disease and in the response to the associated pharmacological treatments. Genetic polymorphism may be, at least in part, responsible for both susceptibility to disease and inter-individual variability in response to pharmacological treatments.